glp-1 approved for sleep apnea Did You Know? The FDA has approved GLP-1 treatments for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This breakthrough provides a new GLP1 medication for sleep apnea

Standard protocol combines once-weekly Mounjaro (subcutaneous) with twice-weekly Lipo C (intramuscular), spaced 34 days apart to avoid same-day injection site overlap

However, anyone can suffer from a vitamin B-12 deficiency

You guessed it: fat. The substitution of muscle with fat that so often accompanies aging makes itself known in many ways, including (but not limited to) a slowed metabolism

The patient characteristics have been previously reported (Lin et al, 2022)

Because of this lipophilicity, ALCAR can easily cross the highly restrictive blood-brain barrier, allowing it to deliver targeted metabolic support directly to energy-starved neurons and glial cells in the brain